Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Latest share price
SEK
20 Nov 2026 16:57 CET
Fair value range
SEK
17 Aug 2026
Market cap
SEK
m
Next report
26 Nov 2026
FluoGuide
Healthcare
2026-10-05
FluoGuide has enrolled the first patient in its US Phase II CT-006 trial of FG001 in newly diagnosed high-grade glioma (HGG), marking the start of active recruitment in...
News
Jesper Ingildsen
Oliver Røst Benneballe
First US HGG patient enrolled - important clinical milestone
Adds Leica as fifth medtech partner
Pipeline progression on track - Q2 review
FluoGuide
Healthcare
2026-10-05
FluoGuide has announced a non-exclusive collaboration with Leica Microsystems focused on the use of FG001 together with Leica’s surgical microscopy platform in...
News
Jesper Ingildsen
Oliver Røst Benneballe
First US HGG patient enrolled - important clinical milestone
Adds Leica as fifth medtech partner
Pipeline progression on track - Q2 review
FluoGuide
Healthcare
2026-08-25
FluoGuide’s Q2 results were slightly more cost-heavy than we expected, reflecting higher R&D expenses related to the ongoing US HGG study. However, we continue to...
Post-Results Note
Jesper Ingildsen
Oliver Røst Benneballe
First US HGG patient enrolled - important clinical milestone
Adds Leica as fifth medtech partner
Pipeline progression on track - Q2 review
Price
Fair range high value
Fair range low value
Year
2024
2025
2026e
2027e
2028e
EPS
-2.23
-2.81
-3.93
-4.67
-8.47
EPS (Adj.)
-2.23
-3.06
-3.93
-4.67
-8.47
Sales Growth
EPS Growth (Adj.)
P/E
P/E (Adj.)
EV/EBITA
-7.5
-6.7
-5.0
-5.3
-4.3
EV/EBITDA
-7.6
-6.8
-5.1
-5.3
-4.3
Learn more
Sector
Healthcare
Country
Sweden
Tickers
FLUO@SS, FLUO.ST
CEO
Morten Albrechtsen
CFO
Ole Larsen
Webpage
fluoguide.com
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB